138 related articles for article (PubMed ID: 9126229)
1. Prostate-specific antigen as a screening test. The Austrian experience.
Reissigl A; Bartsch G
Urol Clin North Am; 1997 May; 24(2):315-21. PubMed ID: 9126229
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen as a screening test for prostate cancer. The United States experience.
Arcangeli CG; Ornstein DK; Keetch DW; Andriole GL
Urol Clin North Am; 1997 May; 24(2):299-306. PubMed ID: 9126227
[TBL] [Abstract][Full Text] [Related]
7. The clinical usefulness of prostate specific antigen: update 1994.
Partin AW; Oesterling JE
J Urol; 1994 Nov; 152(5 Pt 1):1358-68. PubMed ID: 7523702
[TBL] [Abstract][Full Text] [Related]
8. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
9. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
[TBL] [Abstract][Full Text] [Related]
11. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
[TBL] [Abstract][Full Text] [Related]
13. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
14. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
16. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
[TBL] [Abstract][Full Text] [Related]
17. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
Raviv G; Zlotta AR; Janssen Th; Descamps F; Vanegas JP; Verhest A; Schulman CC
Cancer; 1996 May; 77(10):2103-8. PubMed ID: 8640677
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
19. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
